Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used to preserve and improve bone health in patients with cancer because they inhibit osteoclast-mediated bone resorption. In addition to their effects on bone, preclinical evidence strongly suggests that N-BPs exert anticancer activity without the involvement of osteoclasts by interacting with macrophages, endothelial cells and tumor cells, and by stimulating the cytotoxicity of γδ T cells, a subset of human T cells. This review examines the current insights and fronts of ongoing preclinical research on N-BPs' antitumor activity.
Clézardin
Philippe
P
INSERM, Research Unit U664, University of Lyon-1, Faculty of Medicine Lyon-Est (domaine Laennec), rue Guillaume Paradin, 69372 Lyon Cedex 08, France. philippe.clezardin@inserm.fr
D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology / Q000494:pharmacology*; D001862:Bone Resorption / Q000188:drug therapy; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology; D004164:Diphosphonates / Q000276:immunology / Q000494:pharmacology*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005544:Forecasting; D006801:Humans; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D016513:Mice, SCID; D009369:Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D010010:Osteoclasts / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
D000970:Antineoplastic Agents; D004164:Diphosphonates